Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 22477481)

  • 1. [Staging with 18F-FDG-PET/CT influences stage-specific survival in advanced non-small cell lung cancer (NSCLC)].
    Tönnies S; Bauer TT; Misch D; Boch C; Blum T; Bittner RC; Förster GJ; Kollmeier J
    Pneumologie; 2012 Apr; 66(4):212-7. PubMed ID: 22477481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
    Liao S; Penney BC; Zhang H; Suzuki K; Pu Y
    Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative 18F-2-fluorodeoxyglucose PET/CT predicts good cancer specific survival in patients with a suspicion of recurrent ovarian cancer.
    Hebel CB; Behrendt FF; Heinzel A; Krohn T; Mottaghy FM; Bauerschlag DO; Verburg FA
    Eur J Radiol; 2014 Mar; 83(3):463-7. PubMed ID: 24368010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography.
    Billé A; Pelosi E; Skanjeti A; Arena V; Errico L; Borasio P; Mancini M; Ardissone F
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):440-5. PubMed ID: 19464906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT.
    Ohno Y; Koyama H; Onishi Y; Takenaka D; Nogami M; Yoshikawa T; Matsumoto S; Kotani Y; Sugimura K
    Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline SUVmax at PET-CT in stage IIIA non-small-cell lung cancer patients undergoing surgery after neoadjuvant therapy: prognostic implication focused on histopathologic subtypes.
    Lee HY; Lee KS; Park J; Han J; Kim BT; Kwon OJ; Ahn YC; Ahn MJ; Park K; Kim J; Shim YM
    Acad Radiol; 2012 Apr; 19(4):440-5. PubMed ID: 22265854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of recurrence and assessment of post-recurrence survival in patients with extracranial non-small cell lung cancer evaluated by 18F-FDG PET/CT.
    Jiménez-Bonilla JF; Quirce R; Martínez-Rodríguez I; Banzo I; Rubio-Vassallo AS; Del Castillo-Matos R; Ortega-Nava F; Martínez-Amador N; Ibáñez-Bravo S; Carril JM
    Lung Cancer; 2013 Jul; 81(1):71-6. PubMed ID: 23597930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stage migration in planning PET/CT scans in patients due to receive radiotherapy for non-small-cell lung cancer.
    Geiger GA; Kim MB; Xanthopoulos EP; Pryma DA; Grover S; Plastaras JP; Langer CJ; Simone CB; Rengan R
    Clin Lung Cancer; 2014 Jan; 15(1):79-85. PubMed ID: 24238934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
    Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Scheiderbauer J; Budach W; Kotzerke J; Bares R
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):54-9. PubMed ID: 16896660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
    Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
    Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain metastasis in lung cancer. Comparison of cerebral MRI and 18F-FDG-PET/CT for diagnosis in the initial staging.
    Krüger S; Mottaghy FM; Buck AK; Maschke S; Kley H; Frechen D; Wibmer T; Reske SN; Pauls S
    Nuklearmedizin; 2011; 50(3):101-6. PubMed ID: 21165538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective.
    Wang YT; Huang G
    Eur J Radiol; 2012 Aug; 81(8):e903-9. PubMed ID: 22698711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
    Zaizen Y; Azuma K; Kurata S; Sadashima E; Hattori S; Sasada T; Imamura Y; Kaida H; Kawahara A; Kinoshita T; Ishibashi M; Hoshino T
    Eur J Radiol; 2012 Dec; 81(12):4179-84. PubMed ID: 22884163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymph node involvement in T1 non-small-cell lung cancer: could glucose uptake and maximal diameter be predictive criteria?
    Casiraghi M; Travaini LL; Maisonneuve P; Tessitore A; Brambilla D; Agoglia BG; Guarize J; Spaggiari L
    Eur J Cardiothorac Surg; 2011 Apr; 39(4):e38-43. PubMed ID: 21242094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.
    Mertens LS; Mir MC; Scott AM; Lee ST; Fioole-Bruining A; Vegt E; Vogel WV; Manecksha R; Bolton D; Davis ID; Horenblas S; van Rhijn BW; Lawrentschuk N
    Urology; 2014 Feb; 83(2):393-8. PubMed ID: 24468513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma.
    Park JW; Kim JH; Kim SK; Kang KW; Park KW; Choi JI; Lee WJ; Kim CM; Nam BH
    J Nucl Med; 2008 Dec; 49(12):1912-21. PubMed ID: 18997056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
    de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.